ライフサイエンスコーパス: intradermal

1 intradermal 2.22 [1.83-2.69], and 1/27 dose intradermal 1.64 [1.35-2.00]).

2 Intradermal (18)F-FDG can enhance the preclinical invest

3 dose intradermal 2.58 (2.13-3.13), 1/10 dose intradermal 2.22 [1.83-2.69], and 1/27 dose intradermal

4 neous GMFR 1.64 [90% CI 1.36-1.99], 1/3 dose intradermal 2.58 (2.13-3.13), 1/10 dose intradermal 2.22

5 d that scratching behavior, evoked by direct intradermal activation of TRPV4, was critically dependen

6 Novel intradermal devices, including intradermal adapters and disposable-syringe jet injector

7 bility in response to VEGF, administered via intradermal adenoviral delivery or through systemic inje

8 nfused VEGF, ii) ear angiogenic responses to intradermal adenoviral-VEGF injection, and iii) vascular

9 in transplantation experiments revealed that intradermal adipocyte lineage cells are necessary and su

10 ymal interaction layer and the hair follicle-intradermal adipocyte-based tissue interaction layer.

11 or other cell types within the skin, such as intradermal adipocytes, have not been investigated durin

12 Intradermal adipose tissue plays an essential role for h

13 onments that communicate with the follicles: intradermal adipose tissue, innate immune system, sex ho

14 ent dose-response relation was observed with intradermal administration (1/3 dose subcutaneous GMFR 1

15 ythema and induration were more common after intradermal administration (31% erythema for full subcut

16 Intradermal administration had higher a incidence of loc

17 ed multimodal imaging in animal models using intradermal administration of (18)F-FDG for combined dia

18 Intradermal administration of BoNT-A to healthy voluntee

19 Larger and longer studies of intradermal administration of live, attenuated zoster va

20 a minimally invasive delivery system for the intradermal administration of nucleic acids, both plasmi

21 ointestinal symptoms that followed the first intradermal administration of the vaccine resembled thos

22 antibodies to MVA were only detectable after intradermal administration of the vaccine.

23 We aimed to determine whether intradermal administration of zoster vaccine could enhan

24 MTD of Nexvax2 was 150 mug for twice weekly intradermal administration over 8 weeks, which modified

25 4) at 6 weeks post-vaccination compared with intradermal administration which resulted in a significa

26 lumes that are considered to be standard for intradermal administration, and postulate a hydrodynamic

27 ction in antibody titers is possible through intradermal administration.

28 formulation, or placebo, by subcutaneous or intradermal administration.

29 ENvax, or placebo, by either subcutaneous or intradermal administration.

30 controlled transdermal delivery and targeted intradermal administration.

31 Hence, it appears that the combination of intradermal Ag administration and draining LN sampling c

32 Skin biopsy specimens were collected after intradermal allergen challenges, and late-phase response

33 Intradermal allergen immunotherapy suppressed skin late-

34 Repeated low-dose grass pollen intradermal allergen injection suppresses allergen-induc

35 Cutaneous response was measured by intradermal allergen injection.

36 d allergic rhinitis to receive 7 preseasonal intradermal allergen injections (containing 7 ng of Phl

37 Low-dose intradermal allergen, like conventional subcutaneous hig

38 on and (2) between AD participants receiving intradermal and intramuscular vaccination.

39 jet injector was assessed by comparison with intradermal and subcutaneous injection of antigen using

40 unced local reactogenicity was seen with the intradermal and subcutaneous routes than with intramuscu

41 Nanoparticle-based intradermal antigen delivery may therefore provide a new

42 For risk assessment, safe intradermal application of these pigments needs data for

43 The intradermal arm tested daily intradermal injection of ge

44 We treated intradermal B16F10 murine melanoma by intratumoral injec

45 Participants were challenged with intradermal BCG 4 weeks after those who received MVA85A.

46 G-vaccinated volunteers were challenged with intradermal BCG.

47 thin the confines of the bleb created by the intradermal bolus.

48 ompared with noncolonized participants after intradermal but not intramuscular vaccination.

49 ic influenza vaccines after a single dose of intradermal, but not intramuscular, immunization.

50 After intradermal, but not intramuscular, vaccination, partici

51 in combination, as DC-targeted adjuvants for intradermal cancer vaccines.

52 Strikingly, intradermal capsaicin injection promotes itch responses

53 lly, we show that, after a noxious stimulus (intradermal capsaicin injection), these NK-1r on pyramid

54 Employing an intradermal challenge model in mice, we report that cuta

55 We found that after intradermal challenge of mice with the live vaccine stra

56 latory T cells (Tregs) that accumulate after intradermal challenge with a VZV skin test Ag.

57 cell infiltrations in the lesions 48 h after intradermal challenge.

58 anglion pruriceptors, and (iii) injection of intradermal citric acid (pH 3.0) into the nape induced a

59 The magnitude of the single intradermal comparative cervical tuberculin test used to

60 Evaluation of higher dosages, alternative intradermal delivery methods, and the addition of adjuva

61 uld permit the translation of laser-assisted intradermal delivery of a tumor-specific vaccine targeti

62 Microneedle-mediated intradermal delivery of beta-galactosidase and formaldeh

63 The results suggest that intradermal delivery of IPV may lead to dose-sparing eff

64 In the recent past, the intradermal delivery of NPs, via novel dissolving micron

65 Intradermal delivery of partial vaccine doses induced an

66 nic mice following either intraperitoneal or intradermal delivery of the PNA-Antp conjugate.

67 lates in nuclei of keratinocytes, and, after intradermal delivery of the PNA-Antp, chromosomally modi

68 (SKH1) mice with the lambdasupFG1 transgene, intradermal delivery of the TFO, AG30, introduces gene m

69 Intramuscular and intradermal delivery of vaccine were both well tolerated

70 Intradermal delivery of vaccines has been shown to resul

71 decreased anti-vector responses, compared to intradermal delivery.

72 Novel intradermal devices, including intradermal adapters and

73 ne expression in non-human primate skin than intradermal DNA injection, indicating the potential of t

74 given as a full intramuscular or fractional intradermal dose by needle and syringe or disposable-syr

75 ticipants boosted with an 80 mug needle-free intradermal dose of CV7201 achieved titres of 0.5 IU/mL

76 thema for full subcutaneous dose and 77% for intradermal dose).

77 vaccine given subcutaneously or one of four intradermal doses (full, 1/3, 1/10, or 1/27 dose) using

78 The administration of single fractional intradermal doses of IPV by needle and syringe or dispos

79 the antibody titres generated by fractional intradermal doses of IPV did not achieve non-inferiority

80 nogenicity of fractional (one-fifth, 0.1 mL) intradermal doses of the inactivated poliovirus vaccine

81 The two subcutaneous doses and the four intradermal doses were randomised (1.5:1:1:1:1:1) by com

82 - microparticles for targeted and sustained intradermal drug delivery.

83 red to wild-type mice after Leishmania major intradermal ear infection.

84 iple studies have assessed immunogenicity of intradermal fIPV compared with the full intramuscular do

85 s positively correlated with the size of the intradermal fluid bleb.

86 . falciparum rPfHRP2 and total IgG) from the intradermal fluid of live mice in situ, for subsequent d

87 outer skin layers to interface directly with intradermal fluid.

88 Using a model of intradermal footpad injection of Candida albicans, we ob

89 (CVC) and sweat rate were evaluated at four intradermal forearm skin sites: (i) control; (ii) 10 mm

90 havior in early and late phases of the mouse intradermal formalin test of pain, and this in vivo effe

91 en standard-potency or higher-potency mOPV1, intradermal fractional-dose inactivated poliovirus vacci

92 Both topical and intradermal gentamicin administration induced type VII c

93 Herein, we determined whether topical or intradermal gentamicin administration induces type VII c

94 assessed safety and efficacy of topical and intradermal gentamicin in 5 RDEB patients with nonsense

95 Topical and intradermal gentamicin suppresses nonsense mutations and

96 sought to investigate the effect of low-dose intradermal grass pollen administration on cutaneous rea

97 Participants who received 6 fortnightly intradermal grass pollen injections had markedly smaller

98 were higher in the aerosol group than in the intradermal group.

99 ion site reactions were more frequent in the intradermal group.

100 Following intradermal hybrid tracer administration, lymphoscintigr

101 algesia induced by ROS, we demonstrated that intradermal hydrogen peroxide produced dose-dependent hy

102 Dorsal intradermal (i.d.) administration of AYP elicited intens

103 Here we evaluated single versus concurrent intradermal (i.d.) and intramuscular (i.m.) vaccinations

104 ved survival from intraperitoneal (i.p.) and intradermal (i.d.) challenge by L. interrogans serovar C

105 or, which is transmitted in nature following intradermal (i.d.) deposition of parasites by the bite o

106 Intradermal (i.d.) immunization of mice with recombinant

107 Following acute intradermal (i.d.) injection of histamine in the rostral

108 nd on a previous report where we implemented intradermal (i.d.) inoculations to study bacterial disse

109 induce protective immunity in macaques after intradermal (i.d.) or intramuscular (i.m.) delivery of 0

110 Compared to conventional "wet" intradermal (ID) administration, "dry" peptide delivered

111 f different tissues via transcutaneous (TC), intradermal (ID) and intramuscular (IM) injection has th

112 We developed an intradermal (ID) challenge cynomolgus macaque (Macaca fa

113 Intradermal (ID) delivery of influenza vaccine might imp

114 -OVA antibody titer at a level comparable to intradermal (ID) injection and was much more efficient t

115 able, safe and efficient means to administer intradermal (ID) injections.

116 Seven days later, mice received intradermal (id) microinjection of histamine, chloroquin

117 travenous (IV) administration of RAS, not by intradermal (ID) or subcutaneous (SC) vaccination.

118 We evaluated a novel high-dose intradermal (ID) vaccine strategy.

119 ibited tissue inflammation induced by either intradermal IL-23 or TSLP.

120 Furthermore, intradermal immunization of BALB/c mice indicated that h

121 Intradermal immunization of mice against hepatitis B sur

122 Here, we demonstrate that intradermal immunization of mice with 500 ng of the sand

123 V was studied by comparing intramuscular and intradermal immunization of Wistar rats using NanoPass M

124 Moreover, a single intradermal immunization protected mice against melanoma

125 ficacy of BCG-MNAs was comparable to that of intradermal immunization whether it was evaluated by hum

126 r helper and germinal center formation after intradermal immunization with HIV p24-coated polylactic

127 Here we demonstrate that a single low-dose intradermal immunization with lipid-nanoparticle-encapsu

128 To address this issue, we used intradermal immunization with plasmid DNA, a system in w

129 from biopsy specimens of subjects undergoing intradermal immunotherapy had higher expression of the T

130 uate the efficacy and safety of grass pollen intradermal immunotherapy in the treatment of allergic r

131 Intradermal immunotherapy increased serum Phleum pratens

132 In a per-protocol analysis intradermal immunotherapy was further associated with wo

133 vitro treatment of MyD88(-/-) APCs with and intradermal in vivo injections of PARP inhibitor, PJ-34,

134 Intradermal infection of methicillin-resistant Staphyloc

135 ural route of infection with VACV is through intradermal infection of the skin.

136 ed the role of ROS in C57BL/6 mice following intradermal infection with Leishmania amazonensis.

137 Intradermal infection with the ail mutant resulted in an

138 to limit host-protective immunity following intradermal infection with Trypanosoma cruzi.

139 zed by reduced lethality following high-dose intradermal infection, an altered cytokine response in t

140 erial distribution in tissues differed after intradermal infection, compared with the distribution af

141 and induction of adaptive immunity following intradermal infection.

142 r MyD88 in protective immunity to VACV after intradermal infection.

143 local control of virus replication following intradermal infection.

144 murine models of both skin colonization and intradermal infection.

145 Intradermal infections had higher var gene transcript le

146 eutrophilic inflammation in a human model of intradermal inflammation.

147 In contrast, intradermal infusion of HYPER saline did not affect swea

148 Intradermal infusion of HYPER saline increased baseline

149 Furthermore, we examined if local intradermal infusion of hyperosmotic saline affects swea

150 In contrast, local intradermal infusion of hyperosmotic saline did not affe

151 tions separated by 10 weeks, or (3) a single intradermal injection at 10 weeks.

152 ptake of fluorescently labeled albumin after intradermal injection by LECs was similar to that of der

153 Upon intradermal injection in the hindleg, a fraction of both

154 Intradermal injection of (18)F-FDG clearly revealed lymp

155 Intradermal injection of acid generates pain in both rod

156 Furthermore, intradermal injection of ADSCs along with BA-DEG-BA into

157 Angiogenesis induced by tumors arising from intradermal injection of B16 F1 melanoma cells was also

158 rin (BCG) and subsequent activation using an intradermal injection of BCG in complete Freund adjuvant

159 Superficially applied capsaicin and intradermal injection of beta-alanine, an MrgprD agonist

160 Intradermal injection of bile acids and a TGR5-selective

161 ity of the skin swelling induced by means of intradermal injection of C3a or C5a required that mast c

162 and reconstituted with autologous PBMCs, the intradermal injection of CCL18 led to the cutaneous recr

163 The intradermal arm tested daily intradermal injection of gentamicin solution (8 mg) or p

164 ays expressed in psoriatic lesions, a single intradermal injection of IFN-gamma was administered to a

165 local abrogation of IkappaBzeta function by intradermal injection of IkappaBzeta siRNA abolished pso

166 Finally, intradermal injection of IL-17A in standard diet-fed mic

167 Intradermal injection of IL-23 bypassed the requirement

168 skin lesions were induced in C57BL/6 mice by intradermal injection of IL-23 in the ear or dorsum.

169 onstrated that high pressure, resulting from intradermal injection of large liquid volumes, facilitat

170 a comparable dose-dependent vascular leak to intradermal injection of LTC4 or LTD4 and an augmented r

171 subjected to the identical CHMI protocol by intradermal injection of P. falciparum sporozoites.

172 Wheal and flare responses were induced by intradermal injection of PAF, codeine and histamine in 1

173 the skin and surrounding hair follicles via intradermal injection of recombinant R-spondin2 protein.

174 h to address this question, and we find that intradermal injection of S1P induced significant licking

175 is when administered 2 days after orthotopic intradermal injection of the cells, or when treatment st

176 TRPM3-expressing somatosensory neurons, and intradermal injection of the compound induced a TRPM3-de

177 Subcutaneous, intramuscular and intradermal injection of the LNP-encapsulated mRNA trans

178 Repeated intradermal injection of the selective mu-opioid recepto

179 ous inflammation was induced in the thigh by intradermal injection of tuberculin.

180 protection from lethal disease is induced by intradermal injection of vaccinia virus, whereas a prote

181 Furthermore, concomitant intradermal injection of WBM EA extract in mice effectiv

182 , and a cynomolgus monkey by subcutaneous or intradermal injection to assess cytotoxicity or host res

183 mug keyhole limpet haemocyanin) via monthly intradermal injection until progression or intolerance,

184 Mice vaccinated by intradermal injection using the jet injector or subcutan

185 We used a model of intradermal injection with fluorescent-labeled, nonviabl

186 e responses were measured after double-blind intradermal injection with grass and birch pollen.

187 s (NPs), which rapidly drain to the LN after intradermal injection, greatly enhances adjuvant efficac

188 skin architecture and, unlike a conventional intradermal injection, MicronJet administration of a 50m

189 lens were randomized to receive (1) 6 repeat intradermal injections at 2-week intervals of grass poll

190 case of hyperhidrosis means multiple painful intradermal injections by a skilled clinician at 6-month

191 The group receiving intradermal injections had the greatest number of advers

192 ured the magnitude of cutaneous responses to intradermal injections of C3a or C5a and the extent of I

193 influences (1) the cells' responsiveness to intradermal injections of C3a or C5a or (2) the extent o

194 y randomly generated sequence to receive two intradermal injections of either MVA85A or placebo.

195 Furthermore, intradermal injections of HP-NAP-encoding adenovirus in

196 Furthermore, similar intradermal injections of small interfering RNA (siRNA;

197 grass allergen Phl p 5 per injection), (2) 2 intradermal injections separated by 10 weeks, or (3) a s

198 trast to the overt skin irritation caused by intradermal injections.

199 Intradermal inoculation of DENV protease packaged in ade

200 rol Leishmania major infection in vitro, and intradermal inoculation of Leishmania resulted in a more

201 Intradermal inoculation with the F. tularensis live vacc

202 ess invasive routes, such as subcutaneous or intradermal inoculations are rare, even though the shari

203 differential nerve block on itch produced by intradermal insertion of spicules from the pods of a cow

204 ive immune protection in mice against lethal intradermal, intraperitoneal and intranasal challenges w

205 3 [38%]), higher-potency mOPV1 (6/21 [29%]), intradermal IPV (9/16 [56%]), GlaxoSmithKline intramuscu

206 intramuscular IPV, and 21 (36%) of 49 after intradermal IPV (p<0.0001).

207 intramuscular IPV, and 24 (59%) of 41 after intradermal IPV (p<0.0001).

208 One fractional dose of intradermal IPV gave lower seroconversion (10%-40%), but

209 Intradermal IPV shows promise as a means to decrease the

210 Intradermal IPV was less immunogenic.

211 Importantly, painless intradermal jet delivery of DNA was as effective as deli

212 Differences in titer observed between intradermal jet injected and needle injected animals ref

213 cycles of combination chemotherapy, then an intradermal lower abdominal injection of granulocyte-mac

214 levels of splenic IL-17 were observed after intradermal LVS infection only in IL-10(-/-) mice.

215 Ex vivo intradermal microdialysis combined with culture media an

216 In Protocol 2, an intradermal microdialysis fibre was placed in the skin o

217 te day, subjects were instrumented with four intradermal microdialysis fibres on the forearm and each

218 Laser Doppler flowmetry, combined with intradermal microdialysis of l-N(G)-monomethyl-l-arginin

219 vascular conductance were measured over two intradermal microdialysis probes, one perfused with ISO

220 e used laser Doppler flowmetry combined with intradermal microdialysis to measure skin blood flow (Sk

221 Intradermal microdialysis was utilized for up to 24h aft

222 forearm skin sites continuously perfused via intradermal microdialysis with: (1) lactated Ringer solu

223 tivity were assessed pharmacologically using intradermal microdialysis.

224 In this study, we use an intradermal model of infection to study early innate imm

225 and decreased immune cell infiltration in an intradermal model of infection yet still elicited protec

226 ogenic than wild-type VACV in intranasal and intradermal models of infection.

227 Using a murine model of intradermal MRSA infection, the therapeutic efficacy of

228 sol MVA85A and intradermal saline placebo or intradermal MVA85A and aerosol saline placebo.

229 Intradermal MVA85A was associated with expected mild loc

230 Intradermal MVA85A, a candidate vaccine against tubercul

231 cobacterial immunity could be assessed using intradermal Mycobacterium bovis bacille Calmette-Guerin

232 ved that mice were best protected against an intradermal needle challenge with Leishmania major and s

233 Ex vivo intradermal neonatal porcine skin penetration of VD3 NMP

234 ng misclassified, with the most common being intradermal nevi.

235 Common classification errors included intradermal nevus misclassified as basal cell carcinoma

236 mRNA vaccination by needle-free intradermal or intramuscular device injection induced vi

237 Conversely, intradermal or intramuscular needle-syringe injection wa

238 ot significantly different when given by the intradermal or intramuscular route.

239 sessed for eligibility, 347 of whom received intradermal or intramuscular vaccination per label and w

240 malaria-naive individuals were inoculated by intradermal or intravenous injection with cryopreserved,

241 mmediate clinical hypersensitivity following intradermal OVA challenge.

242 Intradermal priming of engrafted NSG-SGM3 mice with a ch

243 tologic examination showed heavily pigmented intradermal proliferation of large, epithelioid melanocy

244 y be involved in the scratching responses to intradermal pruritogens, this is unlikely to be due to a

245 the administration of sequential doses of an intradermal rabies vaccine was shown to result in reduce

246 Intradermal recruitment of CD8(+) T cells by CXCL10 is a

247 EMLA by the intravenous, intraperitoneal, or intradermal route and evaluated for clinical and patholo

248 influenza virus antigen administered by the intradermal route and the intramuscular route have not b

249 oliovirus vaccine (fIPV) administered by the intradermal route delivers one fifth of the full vaccine

250 n (HA), by the intramuscular route or by the intradermal route using the Mantoux technique.

251 , such as increased vaccine dose, use of the intradermal route, and addition of adjuvants, could impr

252 inactivated influenza A/H5N1 vaccines by the intradermal route.

253 ur-fold rise in titres was also lower by the intradermal route.

254 of TDV 90 days apart via the subcutaneous or intradermal routes.

255 By contrast, an intradermal S. aureus challenge promoted MyD88-dependent

256 nvelopes into two groups: aerosol MVA85A and intradermal saline placebo or intradermal MVA85A and aer

257 , pegylated IFN-alpha2b , or ribavirin using intradermal, scratch, and/or patch tests, as well as lym

258 x trials), sublingual (four trials), oral or intradermal SIT in children/adults allergic to house dus

259 with WT were injected 12 h later at the same intradermal site with purified LPS, Y. pestis did not pr

260 Intradermal skin testing of the clinically important ant

261 hy BCG-naive adults were assigned to receive intradermal standard-dose BCG SSI (group A), standard-do

262 We hypothesized that prolonged intradermal suture lifetime can decrease scar spread in

263 Prolonged intradermal suture support leads to significantly decrea

264 ead over time can benefit from longer-acting intradermal sutures.

265 This results in intradermal tattooing of the topical product.

266 ious stings, we studied by BAT and augmented intradermal test (IDT) (10 microg/ml) two groups: (1) wi

267 Lab ApS, Denmark), skin prick test (SPT) and intradermal test (IDT).

268 Intradermal test was marginally positive at 0.1 mg/ml, a

269 (98.7%) patients tolerated the simultaneous intradermal test without any side-effects.

270 For intradermal testing and allergen immunotherapy, a good k

271 Skin intradermal testing and patch testing with delayed readi

272 In vivo allergenic potency was determined by intradermal testing of 51 Japanese adults with positive

273 s based on sensitization rates identified by intradermal testing or serum testing for allergen-specif

274 ectively explored the safety of simultaneous intradermal testing.

275 hylaxis was confirmed in six cases: positive intradermal tests (n = 4), a syndromic reaction during s

276 pha-associated exanthemas displayed positive intradermal tests to PEG-IFNs but not to conventional IF

277 vespid stings and positive ImmunoCAP and/or intradermal tests to vespid venoms were studied.

278 Standardized skin prick and intradermal tests were carried out with a panel of PPIs.

279 Skin prick and intradermal tests with cetuximab were clearly positive i

280 seven of the eight patients showed positive intradermal tests with Glucantime((R)) dilutions reading

281 end points, nasal symptoms were worse in the intradermal treatment group, as measured based on daily

282 sh-colored melanocytic BAP1-mutated atypical intradermal tumors (MBAITs).

283 with AD and nonatopic participants receiving intradermal vaccination and (2) between AD participants

284 s study was to compare antibody responses to intradermal vaccination in participants with moderate/se

285 overt skin irritation, in marked contrast to intradermal vaccination that provoked severe inflammatio

286 Intradermal vaccination was done using the NanoPass Micr

287 ogenicity were analyzed up to 52 weeks after intradermal vaccination with 5 x 10(7) plaque-forming un

288 ed (3:2) to receive sunitinib plus up to ten intradermal vaccinations of IMA901 (4.13 mg) and granulo

289 Intradermal vaccinations were given until toxicity or tu

290 ced transdermal drug delivery and "targeted" intradermal vaccine administration.

291 High-dose intradermal vaccine is an alternative to standard vaccin

292 We evaluated an intradermal vaccine using HIV-1 p24 Gag peptide-conjugat

293 the extent of erythema and induration after intradermal VZV antigen injection.

294 V) vectors for gene delivery to the TG after intradermal whiskerpad delivery in mice.

295 ene delivery to TG sensory neurons following intradermal whiskerpad injection.

296 Intradermal zoster vaccine showed a greater increase in

297 l zoster vaccine, 35 to receive the 1/3 dose intradermal zoster vaccine, 34 to receive the 1/10 dose

298 zoster vaccine, 34 to receive the full dose intradermal zoster vaccine, 35 to receive the 1/3 dose i

299 zoster vaccine, 34 to receive the 1/10 dose intradermal zoster vaccine, and 34 to receive the 1/27 d

300 ter vaccine, and 34 to receive the 1/27 dose intradermal zoster vaccine.